Recursion outlines $375M 2026 cash OpEx guidance while advancing first Genentech neuroscience target

We are no longer just discussing the potential of our platform." (CEO, President & Director Najat Khan) "We now have 5 clinical stage programs, including REC-4881 in FAP, where we have generated some ...
GEN - Genetic Engineering and Biotechnology News

Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI Map

Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on ...

Roche Advances AI-Derived Drug Target With Partner Recursion

Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an ...
unite

Recursive Commits Most of Its Raise to AWS Compute Capacity

Recursive, the AI research company led by Richard Socher, has signed a multi-year, $410 million agreement with Amazon Web Services (AMZN) to run its automated AI research system, putting the bulk of ...